Navigation Links
NPS Pharmaceuticals Reports 2007 Financial Results
Date:3/13/2008

nt and chief executive officer of NPS, stated: "After implementing a new business plan in 2007, raising significant capital and obtaining regulatory clarity from the FDA, NPS now has the direction, the resources, and the capabilities to develop its products in specialty indications with high unmet medical needs, including short bowel syndrome and hypoparathyroidism. With a two to three year cash runway, I am confident that NPS is well-positioned to advance its pipeline and achieve commercial success."

2007 Accomplishments

During 2007, NPS reported the following accomplishments:

-- Refocused its business on specialty indications for gastrointestinal

and endocrine disorders with high unmet medical need

-- Raised more than $275.0 million through the issuance of royalty-backed

and convertible notes and the monetization of non-core assets

-- Achieved net operating cash inflow of $27.6 million for 2007 as

compared to a net operating cash outflow of $103.9 for 2006

-- Retired $191.0 million in convertible debt due in 2008

-- Completed a Phase 3 study of GATTEX(TM) (teduglutide) in short bowel

syndrome (SBS) patients who are dependent on parenteral nutrition (PN)

-- Secured an ex-North America partnership for GATTEX with Nycomed

-- Defined a clinical strategy and obtained orphan drug status for NPSP558

(parathyroid hormone 1-84 [rDNA origin injection]) as a potential

therapy for hypoparathyroidism

Francois Nader, M.D., chief executive officer-elect, stated: "We are committed to executing an ambitious clinical program in 2008. The top-line results from our Phase 3 extension study of GATTEX in patients with short bowel syndrome support our plans to initiate a confirmatory Phase 3 study of GATTEX in this indication in the third quarter of this year. We also expect to launch a pivotal trial for our PTH 1-84 compound, NPSP558, in patients with hypoparathy
'/>"/>

SOURCE NPS Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
2. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
3. Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference
4. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
5. Sagent Pharmaceuticals Launches Cefazolin for Injection, USP
6. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs
8. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
9. Onyx Pharmaceuticals to Present at Cowen and Company Health Care Conference
10. Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
11. VIA Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... New York (PRWEB) December 23, 2014 According ... the Long Island Affiliate of ITRA Global, the national office ... but steady recovery. This is evidenced by the third ... strong stock market. Low energy costs have held inflation ... The only negative is the housing market remaining soft. , ...
(Date:12/24/2014)... , Dec. 23, 2014 China Biologic ... "Company"), a leading fully integrated plasma-based biopharmaceutical company ... that its majority-owned subsidiary, Shandong Taibang Biological Products ... certification from the China Food and Drug Administration ... facility. As previously disclosed in the Company,s public ...
(Date:12/24/2014)... and NEW YORK , ... from its open-label pilot study of mazindol in children ... Development and Therapy in December 2014 . ... mazindol in children with attention deficit/hyperactivity disorder" ( Konofal ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) shows ...
(Date:12/22/2014)... Dec. 22, 2014 GenomeDx Biosciences today announced ... Cancer Classifier, a genomic test for prostate cancer, was ... men managed by radical prostatectomy without adjuvant therapy. Although ... relatively uncommon, using tumor genomics to identify these men ... is an important advance. The study has been ...
Breaking Biology Technology:ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3
... 27 Warner Chilcott Limited (Nasdaq: WCRX ... Inc. has submitted a New Drug Application for WC ... and Drug Administration. About Warner Chilcott ... currently focused on the women,s healthcare and dermatology segments ...
... Record and A Year,s Supply of Breathalicious ... Sweet at the White HouseLOS ANGELES, March ... Bulletin Board: FVRL), which through its wholly-owned ... consumer-controlled Personal Health Records ("PHRs") ( www.mymedicalrecords.com ...
... to stockholders through liquidationA decisive victory for stockholder ... L.P. ("BVF"), today announced that stockholders of Avigen ... remove the existing Board of Directors of Avigen ... took place earlier today at the special meeting ...
Cached Biology Technology:Warner Chilcott Announces NDA Submission for Low Dose Oral Contraceptive 2Warner Chilcott Announces NDA Submission for Low Dose Oral Contraceptive 3MMR and Dancing Paws to Participate in Joint Sales Effort to Provide Personal Health Records for Pets 2MMR and Dancing Paws to Participate in Joint Sales Effort to Provide Personal Health Records for Pets 3MMR and Dancing Paws to Participate in Joint Sales Effort to Provide Personal Health Records for Pets 4Biotechnology Value Fund, L.P. Announces Overwhelming Support to Remove the Board of Directors of Avigen, Inc. at Special Meeting of Stockholders 2
(Date:12/10/2014)... , Dec. 8, 2014 You,ve been here before: ... but can,t remember your password, site key or the answer ... your first grade teacher? Today, Hoyos ... app that will finally put an end to the ... 1U TM . 1U leverages a user,s smartphone to ...
(Date:12/10/2014)... , Dec. 9, 2014 CIE San Diego ... that provides the connective tissue that enhances care coordination ... to easily share client-level information; earned a second $1 ... to organizations serving seniors aging in community and; will ... on December 11 th 4-6p. CIE ...
(Date:12/5/2014)... VIEW, Calif. , Dec. 4, 2014 /PRNewswire/ ... safety has boosted investments in new testing and ... has also given rise to a range of ... by the requirements of Generation Y, which is ... technologies. As a result, product development strategies of ...
Breaking Biology News(10 mins):The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4
... In an effort to make data storage more cost-effective, ... Taiwan and the Karlsruhe Institute of Technology in Germany have ... that uses ultraviolet (UV) light to make it possible to ... the AIP,s Applied Physics Letters , consists of a ...
... assistant professor on the Florida campus of The Scripps ... grants to study a critical component of long-term memory ... years from the prestigious Whitehall Foundation to study the ... kinesin. In this study, he will use the marine ...
... SAN DIEGO -- Lung cancer is the most commonly diagnosed ... unless caught early, but scientists are working on ways to ... of scientists will gather in San Diego at the San ... the AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer: ...
Cached Biology News:Scripps Research Scientist wins pair of grants to study critical component of memory 2Lung cancer conference to focus on new diagnostic techniques, potential treatments 2
... Varians unique collision reaction interface (CRI) ... of troublesome spectroscopic interferences. The result ... without the worry of complex multipole ... cells. And, by coupling autotuning of ...
a1-Antitrypsin (human, alpha-1 AT)...
... Microsomal vesicles are used to study ... proteins. Processing events such as signal ... core glycosylation can be examined by ... in vitro in the presence of ...
... Bio luciferase assay. Mo Bio Laboratories offers the ... you to certify your products ATP-Free with a ... deliver them to your customers in a timely ... 3.5 x 10-12 /l, which will allow you ...
Biology Products: